A Look at DARPA’s mRNA Plan & Head Scientist: Is Aerosol Delivery Next?

As the COVID-19 pandemic becomes a nightmare of the past—failed mRNA gene-damaging jabs and all—the ostensibly well-planned clandestine path leading up to the unforgettable World Health Organization (WHO) declaration to shut down the world due to a global pandemic caused by a novel respiratory virus cannot be forgotten. After all, they’ve repeatedly forewarned society that it will happen again. With that in mind, one aspect of the strategy that demands constant highlighting is the well-funded, decades-long pursuit to introduce mRNA gene technology into the human body. The programmable gene expression quest has been a strategic one initiated by the United States military under the arm of its Defense Advanced Research Projects Agency, or DARPA.

Besides the peculiar October 2019 coincidences of the deep-state connected Event 201 and the U.S. Defense Department’s 2019 Military World Games held in Wuhan, China (the deceit-ridden epicenter of the pandemic’s origin), in June 2019, DARPA—which has been developing mRNA technology with Moderna since 2013—funded a $21.9 million gene modulation research effort targeting influenza pandemics. Explaining its “multifaceted research effort aimed at temporarily modulating gene expression using RNA-based techniques,” DARPA partner Emory University researchers noted in a June 28, 2019 statement:

“Drugs developed through the up to $21.9 million effort, which is funded by the Defense Advanced Research Projects Agency (DARPA), would provide rapid response against a broad range of flu variants—and could potentially be used against other viruses in the future. The RNA-based drugs could be delivered to the lungs through a nebulizer or inhaler, which are well-established techniques.”

Researchers at the Georgia Institute of Technology led the planned four-year project, including scientists from Duke University, Emory University, the University of Georgia, the University of Louisiana, Rockefeller University, and Acorda Therapeutics. Likewise, the U.S. Centers for Disease Control and Prevention (CDC) partnered with the group to provide funding separate from DARPA’s PREPARE (Preemptive Expression of Protective Alleles and Response Elements) Initiative.

In its preemptive May 2018 announcement of the PREPARE initiative, DARPA reported, “PREPARE aims to develop [a] new class of generalizable medical countermeasures that safely and temporarily tune activity of protective genes.” The press release adds that the envisioned PREPARE technologies would supply an alternative that preserves the genetic code exactly as it is and “only temporarily modulates gene activity via the epigenome and transcriptome, which are the cellular messages that carry out DNA’s genetic instructions inside cells.”

DARPA remarked this accomplishment would establish the capability to deliver “programmable, but transient gene modulators to confer protection within brief windows of time for meaningful intervention.” Hmm…that sounds dangerous. And, alas, we now know DARPA’s first attempt at mRNA modification failed the American people. Renee Wegrzyn, PREPARE program manager, remarked at the time:

“Focusing only on programmable modulation of gene expression enables us to provide specific, robust protection against many threats at once, with an effect that carries less risk, is limited but tunable in duration, and is entirely reversible.

Success will hinge on developing new tools for targeted modulation of gene expression inside the body. Researchers must identify the specific gene targets that can confer protection, develop in vivo technologies for programmable modulation of those gene targets, and formulate cell- or tissue-specific delivery mechanisms to direct programmable gene modulators to the appropriate places in the body. Although the immediate program goal is to develop defenses against one of the four focus areas determined by DARPA, the ultimate objective of PREPARE is to develop a modular, threat-agnostic platform solution with common components and manufacturing architecture that can be readily adapted to diverse and emerging threats.”

In the June 27, 2019, DARPA partnership announcement, Philip Santangelo, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University and longtime mRNA researcher, noted that “viruses are good at adapting, but they are not very good at adapting when we can use orthogonal methods of fighting them.” DARPA explained the objective of Santangelo and his crew, remarking:

“A team led by the Georgia Institute of Technology, under principal investigator Dr. Phil Santangelo, aims to develop novel gene therapies to enable protection against a wide range of influenza strains by delivering mRNA-encoded programmable gene modulators and programmable antivirals to the lungs to boost host defenses and/or immediately halt viral replication. The team will also pursue strategies to improve the immune responsiveness and efficacy of current influenza vaccines.”

With an “incredibly ambitious” goal in 2019 of having drugs ready for clinical trials by the end of the four-year research period, the group knew its work would open many doors for entirely new classes of drugs. Santangelo remarked, “Conceptually, the ability to temporarily modulate genes to make people more resistant to a pathogen is incredibly exciting.” Noting current vaccines are not ideal for their military-inspired purpose, the researchers go on to explain:

“Vaccines have a well-established protective capacity against seasonal flu, but they take time to act and become obsolete because of continuous evolution of the flu virus. This project proposes to enact rapid modulation of host responses to the flu virus by manipulating RNA in cells. RNA is the transient template that cells use to make proteins, and rapid RNA regulation, therefore, has the potential to impact acute symptoms and transmission in settings of a flu epidemic with aggressive strains where vaccines would be largely ineffective.”

Santangelo, who was already working with the components that make up the COVID-19 vaccine when the pandemic conveniently hit, offered his insight and assured communities across the country that the vaccine was safe and effective as it arrived in late 2020. When answering the question, “Can I get COVID-19 from the vaccine?” Santangelo, who is working with CRISPR on mRNA treatments, replied, “The mRNA is only making the spike protein. It is not the whole virus; it’s only a part of it. You can’t get the virus from the mRNA vaccine.” 

That is a concerning and wrong response, indeed. But it’s not surprising, given Santangelo’s ongoing mRNA work with DARPA. Without a doubt, Santangelo is a critical actor in the unscrupulous advancement of mRNA technology. In October 2022, highlighting his mRNA achievements, DARPA stated:

“In the field of mRNA-based therapeutics, [Santangelo] has spearheaded the development of a molecular toolbox for characterizing mRNA delivery and the development of new applications of mRNA, including the delivery of mRNA-encoded antibodies and CRISPR proteins to mucosal interfaces, with emphasis on the lung and female reproductive tract.”

As humanity moves past COVID-19 and realizes that Santangelo’s focus—funded by American taxpayers via DARPA, the CDC, alongside the unscrupulous Bill Gates—is new mRNA applications, including mRNA-encoded antibodies and CRISPR proteins, with emphasis on lungs and female reproduction, should there be concern? The answer is a loud “YES.”

On August 23, 2023, carelessly touting the success of the COVID-19 shots, President Biden announced his office was awarding Santangelo with a three-year, $24.8 million cooperative agreement from the Advanced Research Projects Agency for Health (ARPA-H) to use mRNA technology “to train our own immune systems to fight cancer, autoimmune disorders, and infectious diseases more effectively.”

In addition to working with the Department of Defense, CDC, and Gates on a programmable mRNA therapies for Americans, Santangelo is co-founder of Tether Therapeutics—a company “revolutionizing aerosol gene delivery,” that has enjoyed long-standing support from DARPA and The Bill and Melinda Gates Foundation). Conflict of interest, perhaps?

Regardless, Santangelo seems the perfect fit for DARPA and the deep state as they march to program and control each of us while merging humans and technology. Humble and honest experts agree that the mRNA jab experiment on society failed, leaving millions suffering and others unfortunately deceased. What’s next? mRNA Aerosols sprayed into the air? Will Americans be made aware beforehand? They are, after all, footing much of the bill.